Acurx Pharmaceuticals, Inc. (ACXP) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+374.0%

$5.07

vs $1.07 price

Levered DCF

$5.04

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-10.22

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-0.47×	-0.93×	-3.33×	-3.56×	-3.46×	-17×	-13.15×
P/B	0.71×	22.54×	10.4×	5.88×	3.56×	28.96×	72.2×
P/S	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	0.48×	504.7×	-2.82×	-2.81×	-2.45×	0×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	3.18×	1.19×	2.53×	4.55×	15.71×	6.82×	1.48×
Debt / equity	0×	0×	0×	0×	0×	0.02×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-151.2%	-2292.7%	-312.4%	-165.3%	-102.7%	-170.3%	-723.5%
Return on invested capital	-153.6%	-2292.7%	-312.4%	-165.3%	-103.3%	-166.2%	-723.5%
Return on assets	-103.6%	-365.6%	-189.1%	-129.0%	-96.2%	-142.7%	-234.3%
Free cash flow yield	-181.9%	-74.9%	-20.2%	-17.5%	-11.4%	-4.3%	-6.7%
Earnings yield	-213.4%	-101.7%	-30.0%	-28.1%	-28.9%	-5.9%	-10.0%
Enterprise value	-$3.8M	$10.2M	$41.1M	$33.9M	$31.2M	$75.1M	$56.7M
Net debt / EBITDA	0.95×	-184.19×	0.51×	0.75×	1.02×	0×	0×
Cash conversion cycle (days)	0	0	0	0	0	0	0